Clinical outcomes of a twice daily metronidazole dosing strategy for Bacteroides bloodstream infections
Shah S, Adams K, Clarke L, Ludwig J, McManus D, Nguyen M, Topal J, Shields R. Clinical outcomes of a twice daily metronidazole dosing strategy for Bacteroides bloodstream infections. International Journal Of Antimicrobial Agents 2024, 107403. PMID: 39667533, DOI: 10.1016/j.ijantimicag.2024.107403.Peer-Reviewed Original ResearchClinical failureDosing strategiesClinical outcomesIncreased risk of clinical failureRetrospective chart review of adult patientsChart review of adult patientsReview of adult patientsRate of clinical failureClinical outcomes of patientsRisk of clinical failureAssociated with worse outcomesOutcomes of patientsRetrospective chart reviewBloodstream infectionsMetronidazole doseAdult patientsWorse outcomesIncreased riskMetronidazolePatientsInclusion criteriaBacteroides sppBacteremiaDoseMortalityClinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis
Shah S, Clarke L, Davis M, Topal J, Shields R. Clinical manifestations and treatment outcomes for patients with Pseudomonas endocarditis. Journal Of Antimicrobial Chemotherapy 2024, 79: 2017-2021. PMID: 38958234, DOI: 10.1093/jac/dkae205.Peer-Reviewed Original ResearchPseudomonas endocarditisFirst-lineClinical outcomesShorter time to treatment initiationFactors associated with treatment failureInvestigate clinical outcomes of patientsClinical outcomes of patientsTime to treatment initiationRate of adverse effectsProsthetic valve endocarditisFirst-line therapyOrgan transplant recipientsOutcomes of patientsInvestigate clinical outcomesIntracardiac complicationsDuke criteriaMicrobiological failureDrug discontinuationValve endocarditisCombination therapyTreatment failureTransplant recipientsDay mortalityInitial treatmentClinical benefitClinical outcomes of baloxavir versus oseltamivir in immunocompromised patients
Ringer M, Malinis M, McManus D, Davis M, Shah S, Trubin P, Topal J, Azar M. Clinical outcomes of baloxavir versus oseltamivir in immunocompromised patients. Transplant Infectious Disease 2024, 26: e14249. PMID: 38319665, DOI: 10.1111/tid.14249.Peer-Reviewed Original ResearchLength of stayIntensive care unitBaloxavir groupClinical outcomesSecondary outcomesIntensive care unit length of stayRetrospective study of hospitalized patientsEfficacy of baloxavirResolution of feverImmunocompromised adult patientsStudy of hospitalized patientsRetrospective cohort studyAssociated with longer timeResolution of hypoxiaOseltamivir groupInfluenza subtypesImmunocompromised patientsInfluenza ANo significant differenceMedian timeResistance ratesNeuraminidase inhibitorsRetrospective studyBaseline characteristicsAdult patients